- The French Competition Authority dishes out some €16M in fines for the allegedly anti-competitive tactics employed by Schering-Plough (MRK -0.6%) and Reckitt Benckiser in marketing the opioid addiction treatment Subutex back in 2005.
- The move is tied to a complaint filed by Actavis (ACT -0.2%) unit Arrow Generiques which claims Schering-Plough spoke ill of a generic version during sales calls and "granted pharmacists unjustified discounts to prompt them to stock up on Subutex instead," Reuters notes.
- MRK is "reviewing the decision."
French authority alleges anti-competitive practices in opioid addiction market
Dec 19 2013, 14:21 ET